Effect of omega-3 fatty acids on kidney function after myocardial infarction: The alpha omega trial

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 10, 2014, Pages 1676-1683

  Hoogeveen, Ellen K ^a   Geleijnse, Johanna M ^a   Kromhout, Daan ^a   Stijnen, Theo ^b   Gemen, Eugenie F ^c   Kusters, Ron ^c   Giltay, Erik J ^b  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c JEROEN BOSCH HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER; CREATININE; CYSTATIN C; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; LINOLENIC ACID; MARGARINE; PLACEBO; BIOLOGICAL MARKER; CST3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEALTH STATUS; HEART INFARCTION; HUMAN; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORBIDITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SUPPLEMENTATION; BIOLOGICAL MODEL; BLOOD; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE COURSE; KIDNEY; MIDDLE AGED; MYOCARDIAL INFARCTION; NETHERLANDS; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; RISK; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALPHA-LINOLENIC ACID; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CREATININE; CYSTATIN C; DISEASE PROGRESSION; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FEMALE; FOOD, FORTIFIED; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; LOGISTIC MODELS; MALE; MARGARINE; MIDDLE AGED; MODELS, BIOLOGICAL; MYOCARDIAL INFARCTION; NETHERLANDS; ODDS RATIO; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923828118     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.10441013     Document Type: Article

References (42)

1. Wetzels JF, Kiemeney LA, Swinkels DW, Willems HL, den Heijer M: Age- and gender-specific reference values of estimatedGFR in Caucasians: The Nijmegen Biomedical Study. Kidney Int 72: 632–637, 2007.
2. Kronborg J, Solbu M, Njølstad I, Toft I, Eriksen BO, Jenssen T: Predictors of change in estimated GFR: A population-based 7- year follow-up from the Tromso study. Nephrol Dial Transplant 23: 2818–2826, 2008.
3. Hoogeveen EK, Halbesma N, Rothman KJ, Stijnen T, van Dijk S, Dekker FW, Boeschoten EW, de Mutsert R; Netherlands Cooperative Study on the Adequacy of Dialysis-2 (NECOSAD) Study Group: Obesity and mortality risk among younger dialysis patients. Clin J Am Soc Nephrol 7: 280–288, 2012.
4. Eijkelkamp WB, de Graeff PA, van Veldhuisen DJ, van Dokkum RP, Gansevoort RT, de Jong PE, de Zeeuw D, Hillege HL; Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study Group: Effect of first myocardial ischemic event on renal function. Am J Cardiol 100: 7–12, 2007.
5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296–1305, 2004.
6. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351: 1285–1295, 2004.
7. O’Hare AM, Bertenthal D, Covinsky KE, Landefeld CS, Sen S, Mehta K, Steinman MA, Borzecki A, Walter LC: Mortality risk stratification in chronic kidney disease: One size for all ages? J Am Soc Nephrol 17: 846–853, 2006.
8. Appel LJ, Wright JT Jr., Greene T, Kusek JW, Lewis JB, Wang X, Lipkowitz MS, Norris KC, Bakris GL, Rahman M, Contreras G, Rostand SG, Kopple JD, Gabbai FB, Schulman GI, Gassman JJ, Charleston J, Agodoa LY; African American Study of Kidney Disease and Hypertension Collaborative Research Group: Longterm effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med 168: 832–839, 2008.
9. Gopinath B, Harris DC, Flood VM, Burlutsky G, Mitchell P: Consumption of long-chain n-3 PUFA, a-linolenic acid and fish is associated with the prevalence of chronic kidney disease. Br J Nutr 105: 1361–1368, 2011.
10. Lauretani F, Semba RD, Bandinelli S, Miller ER 3rd, Ruggiero C, Cherubini A, Guralnik JM, Ferrucci L: Plasma polyunsaturated fatty acids and the decline of renal function. Clin Chem 54: 475–481, 2008.
11. Kromhout D, Giltay EJ, Geleijnse JM; Alpha Omega Trial Group: n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 363: 2015–2026, 2010.
12. Geleijnse JM, Giltay EJ, Schouten EG, de Goede J, Oude Griep LM, Teitsma-Jansen AM, Katan MB, Kromhout D; Alpha Omega Trial Group: Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4,837 post-myocardial infarction patients: Design and baseline characteristics of the Alpha Omega Trial. Am Heart J 159: 539–546, 2010.
13. Giltay EJ, Geleijnse JM, Schouten EG, Katan MB, Kromhout D: High stability of markers of cardiovascular risk in blood samples. Clin Chem 49: 652–655, 2003.
14. Shlipak MG, Matsushita K, Ärnlöv J, Inker LA, Katz R, Polkinghorne KR, Rothenbacher D, Sarnak MJ, Astor BC, Coresh J, Levey AS, Gansevoort RT; CKDPrognosis Consortium: Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 369: 932–943, 2013.
15. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS; CKD-EPI Investigators: Estimating glomerular filtration rate fromserum creatinine and cystatin C. N Engl J Med 367: 20–29, 2012.
16. Grubb A, Blirup-Jensen S, Lindström V, Schmidt C, Althaus H, Zegers I; IFCC Working Group on Standardisation of Cystatin C (WG-SCC): First certified reference material for cystatin C in human serumERM-DA471/IFCC. Clin ChemLab Med 48: 1619–1621, 2010.
17. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration: Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53: 766–772, 2007.
18. Hoogeveen EK, Geleijnse JM, Kromhout D, Giltay EJ: No effect of n-3 fatty acids on high-sensitivity C-reactive protein after myocardial infarction: The Alpha Omega Trial [published online ahead of print June 17, 2013]. Eur J Prev Cardiol doi: 2047487313494295.
19. Miller ER 3rd, Juraschek SP, Anderson CA, Guallar E, Henoch- Ryugo K, Charleston J, Turban S, Bennett MR, Appel LJ: The effects of n-3 long-chain polyunsaturated fatty acid supplementation on biomarkers of kidney injury in adults with diabetes: Results of the GO-FISH trial. Diabetes Care 36: 1462–1469, 2013.
20. Zoppini G, Targher G, Chonchol M, Ortalda V, Negri C, Stoico V, Bonora E: Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol 7: 401–408, 2012.
21. Senn S, Julious S: Measurement in clinical trials: A neglected issue for statisticians? Stat Med 28: 3189–3209, 2009.
22. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 59: 260–269, 2001.
23. Singh D, Whooley MA, Ix JH, Ali S, Shlipak MG: Association of cystatin C and estimated GFRwith inflammatory biomarkers: The Heart and Soul Study. Nephrol Dial Transplant 22: 1087–1092, 2007.
24. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, Rossert J, Van Lente F, Bruce RD 3rd, Zhang YL, Greene T, Levey AS: Estimating GFR using serum cystatin C alone and in combination with serum creatinine: A pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 51: 395–406, 2008.
25. Grubb A, Björk J, Nyman U, Pollak J, Bengzon J, Ostner G, Lindström V: Cystatin C, a marker for successful aging and glomerular filtration rate, is not influenced by inflammation. Scand J Clin Lab Invest 71: 145–149, 2011.
26. Kelley DS, Siegel D, Fedor DM, Adkins Y, Mackey BE: DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men. J Nutr 139: 495–501, 2009.
27. Ciubotaru I, Lee YS, Wander RC: Dietary fish oil decreases Creactive protein, interleukin-6, and triacylglycerol to HDLcholesterol ratio in postmenopausal women on HRT. J Nutr Biochem 14: 513–521, 2003.
28. Abeywardena MY, Head RJ: Longchain n-3 polyunsaturated fatty acids and blood vessel function. Cardiovasc Res 52: 361–371, 2001.
29. Kromhout D, Yasuda S, Geleijnse JM, Shimokawa H: Fish oil and omega-3 fatty acids in cardiovascular disease: Do they really work? Eur Heart J 33: 436–443, 2012.
30. Adkins Y, Kelley DS: Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. J Nutr Biochem 21: 781–792, 2010.
31. Fassett RG, Gobe GC, Peake JM, Coombes JS: Omega-3 polyunsaturated fatty acids in the treatment of kidney disease. Am J Kidney Dis 56: 728–742, 2010.
32. Donadio JV Jr., Bergstralh EJ, Offord KP, Spencer DC, Holley KE; Mayo Nephrology Collaborative Group: A controlled trial of fish oil in IgA nephropathy. N Engl J Med 331: 1194–1199, 1994.
33. Donadio JV Jr., Larson TS, Bergstralh EJ, Grande JP: A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol 12: 791–799, 2001.
34. Ferraro PM, Ferraccioli GF, Gambaro G, Fulignati P, Costanzi S: Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: A randomized controlled trial. Nephrol Dial Transplant 24: 156–160, 2009.
35. Wong CY, Yiu KH, Li SW, Lee S, Tam S, Lau CP, Tse HF: Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus. Diabet Med 27: 54–60, 2010.
36. Miller ER 3rd, Juraschek SP, Appel LJ, Madala M, Anderson CA, Bleys J, Guallar E: The effect of n-3 long-chain polyunsaturated fatty acid supplementation on urine protein excretion and kidney function: Meta-analysis of clinical trials. Am J Clin Nutr 89: 1937–1945, 2009.
37. Yang Y, Lu N, Chen D, Meng L, Zheng Y, Hui R: Effects of n-3 PUFA supplementation on plasma soluble adhesion molecules: A meta-analysis of randomized controlled trials. Am J Clin Nutr 95: 972–980, 2012.
38. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ: Blood pressure response to fish oil supplementation: Metaregression analysis of randomized trials. J Hypertens 20: 1493–1499, 2002.
39. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky JM: GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulinsensitizing effects. Cell 142: 687–698, 2010.
40. Aukema HM, Lu J, Borthwick F, Proctor SD: Dietary fish oil reduces glomerular injury and elevated renal hydroxyeicosatetraenoic acid levels in the JCR:LA-cp rat, a model of the metabolic syndrome. Br J Nutr 110: 11–19, 2013.
41. Rothman KJ, Greenland S: Modern Epidemiology, 2nd Ed., Philadelphia, Lippincott-Raven, 1998, pp 115–134.
42. Perkins BA, Nelson RG, Ostrander BE, Blouch KL, Krolewski AS, Myers BD, Warram JH: Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: Results of a 4- year follow-up study. J Am Soc Nephrol 16: 1404–1412, 2005